MEDIFAST INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MEDIFAST INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $264.91M | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | $271.47M | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | $220.00M | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | $178.46M | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | $170.63M | Feb 26, 2021 |
| FY2020 | Sep 30, 2019 | $190.06M | Feb 26, 2021 |
| FY2020 | Jun 30, 2019 | $187.10M | Feb 26, 2021 |
| FY2020 | Mar 31, 2019 | $165.88M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $145.84M | Mar 2, 2020 |
| FY2019 | Sep 30, 2018 | $139.24M | Mar 2, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $385.79M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $602.46M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.07B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.60B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $1.53B | Feb 20, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $301.56M | Mar 16, 2018 |
| FY2017 | Dec 31, 2016 | $274.53M | Mar 16, 2018 |
| FY2017 | Dec 31, 2015 | $272.77M | Mar 16, 2018 |
| FY2016 | Dec 31, 2014 | $285.29M | Mar 16, 2017 |
| FY2015 | Dec 31, 2013 | $324.05M | Mar 15, 2016 |
| FY2014 | Dec 31, 2012 | $318.57M | Mar 16, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $275.19M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $444.62M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $775.85M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.14B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $1.13B | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | $199.24M | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | $204.04M | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | $159.30M | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | $135.24M | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | $128.07M | Feb 26, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.67M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.09M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $99.42M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $143.57M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $164.03M | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | $27.99M | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | $34.45M | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | $21.94M | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | $18.48M | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | $19.88M | Feb 26, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.21M) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.88M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $126.40M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $184.81M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $216.24M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $134.16M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $91.04M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $69.06M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $39.63M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $26.86M | Mar 1, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.30M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $4.60M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $4.60M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $4.50M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $4.40M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $2.80M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $2.70M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $2.20M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $1.50M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $2.00M | Mar 1, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $289.40M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $441.75M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $649.45M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $955.61M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $911.36M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $563.66M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $445.82M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $310.84M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $188.18M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $178.81M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.86M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $24.48M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $147.66M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $194.57M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $94.55M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $145.20M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $84.26M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $60.82M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $43.24M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $25.35M | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.61M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $7.45M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $6.48M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $16.68M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $34.21M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $5.89M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $10.06M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $4.94M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $3.24M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $2.88M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $247.97M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $284.21M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $309.91M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $316.21M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $398.33M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $276.08M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $194.65M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $169.43M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $145.93M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $121.22M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.05M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $74.10M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $108.43M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $161.17M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $195.85M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $118.84M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $89.82M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $60.32M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $37.35M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $25.20M | Mar 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $198.92M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $210.11M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $201.48M | Feb 17, 2026 |
| FY2025 | Dec 31, 2022 | $155.04M | Feb 17, 2026 |
| FY2024 | Dec 31, 2021 | $202.47M | Feb 18, 2025 |
| FY2023 | Dec 31, 2020 | $157.25M | Feb 20, 2024 |
| FY2022 | Dec 31, 2019 | $104.83M | Feb 21, 2023 |
| FY2021 | Dec 31, 2018 | $109.11M | Feb 23, 2022 |
| FY2020 | Dec 31, 2017 | $106.56M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $96.02M | Mar 2, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $158.27M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $176.78M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $174.65M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $139.85M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $190.33M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $154.35M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $168.79M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $131.34M | Mar 2, 2020 |
| FY2018 | Jan 1, 2018 | $101.74M | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | $103.76M | Mar 1, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.30M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $90.93M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $94.44M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $87.69M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $104.18M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $163.72M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $76.97M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $81.36M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $75.08M | Mar 1, 2019 |
| FY2018 | Dec 31, 2016 | $52.44M | Mar 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 9 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 12 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 14 | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | 2 | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | 2 | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 26, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 9 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 12 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 13 | Feb 20, 2024 |
| FY2020 | Dec 31, 2020 | 2 | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | 2 | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 26, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10.99M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 10.94M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | 10.90M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | 10.87M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | 11.59M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | 11.77M | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | 11.76M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 11.87M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 11.97M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 11.87M | Mar 16, 2018 |